In partnership with

Your daily edge in private markets

Wondering what’s the latest with crypto treasury companies, Pre-IPO venture secondaries, private credit deals and real estate moves? Join 100,000+ private market investors who get smarter every day with Alternative Investing Report, the industry's leading source for investing in alternative assets.

In your inbox by 9 AM ET, AIR is chock full of the latest insights, analysis and trends that are driving alts. Readers get a weekly investment pick to consider from a notable investor, plus special offers to join top private market platforms and managers.

And the best part? It’s totally free forever.

Subcribe to AIR today

Edwards Lifesciences Corporation DCF Stock Analysis

Here’s my assumptions:

Risk Free Rate (10 Years Interest Rate Swap): 3.97%

Risk Premium (Taken from the Aswath Damodaran equity premium spreadsheet): 4.33%

Interest Rate Spread on The Risk free rate ( For the cost of debt calculation): 2.5%

Historical Data

Revenue growth in the last 10 years (CAGR): 27.09%

Earnings growth in the last 10 years (CAGR): 23.77%

Unlevered Free Cash Flow growth in the last 10 years (CAGR): 12.22%

Future Assumptions

End of Year FCF growth: 6%

Growth until end of 2026: 12%

Growth until end of 2034: 8%

Perpetual growth: 3%

Net Debt: -3.365B

Outstanding Stock Options Present Value Assumption: $0.021B

Restricted Stock Units Present Value Assumption: $0.26B

Stock Valuation based on these assumptions: $114

Last update 08/31/2025

All the content in this newsletter should be taken as informational content only. THIS IS NOT FINANCIAL ADVICE! Do your own Due Diligence before investing or contact a professional financial advisor.

I don’t have a position in Edwards Lifesciences Corporation (EW) and I don’t plan to add a position in the coming days.